The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7–36 amide on gastric acid secretion in humans depends on an intact vagal innervation

A Wettergren, M Wojdemann, S Meisner, F Stadil, J J Holst

Abstract

Background—Glucagon-like peptide-1 (GLP-1) (7–36) amide is an intestinal incretin hormone which also inhibits gastric acid secretion in humans. Its mechanism of action is unclear, but it strongly inhibits vagally induced secretion (sham feeding), suggesting that it could influence vagal activity.

Aim/Methods—The effect of intravenous GLP-1 (7–36 amide) (1 pmol/kg/min) was studied on pentagastrin induced acid secretion in otherwise healthy subjects, previously vagotomised for duodenal ulcer (n=8) and in a group of young (n=8) and old (n=6) healthy volunteers.

Results—Pentagastrin increased acid secretion significantly in all three groups, but the plateau concentration in the vagotomised subjects was lower than in controls. Infusion of GLP-1 (7–36 amide) significantly inhibited acid secretion in the control groups (to 67% (SEM 6) and 74% (SEM 3)% of plateau concentrations in young and old controls, respectively) but had no effect in the vagotomised subjects. Differences in plasma concentrations of GLP-1 (7–36 amide), recovery of gastric marker, duodenal regurgitation, or Helicobacter pylori status could not explain the lack of effect. Blood glucose was lowered equally by GLP-1 (7–36 amide) in all subjects.

Conclusion—The inhibitory effect of GLP-1 (7–36 amide) on acid secretion depends on intact vagal innervation of the stomach.

(Keywords: ileal brake, entero, vagotomy, pentagastrin, proglucagon.)

Glucagon-like peptide-1 (GLP-1) (7–36 amide) is a peptide processed from proglucagon in open type endocrine cells (L cells) in the small intestine and colon,1,2 from which it is released into the circulation in response to feeding.3-6,9 It has attracted considerable interest because of its potent insulinotropic and glucagonostatic effects, whereby it lowers blood glucose. Because of this it has been proposed as a therapeutic agent in the treatment of type 2 diabetes mellitus.10-15 In addition to its glucoregulatory effects GLP-1 (7–36 amide) strongly inhibits gastrointestinal motility and secretion including meal and pentagastrin stimulated acid secretion.16-18 It has, therefore, been suggested to act as an important enterogastrone in humans.16-18

It is not clear by what mechanism(s) GLP-1 (7–36 amide) inhibits acid secretion in humans. Conceivably, it might act locally by inhibiting parietal cell secretion directly or indirectly via a paracrine action of an increased release of somatostatin. It might also act by inhibiting vagal transmission to the parietal cells at the gastric level or by inhibiting vagal efferent activity via a central mechanism. Recent experiments in our laboratory have shown that GLP-1 (7–36 amide) in physiological concentrations almost abolished acid secretion induced by sham feeding, indicating that GLP-1 (7–36 amide) effectively also inhibits neurally induced acid secretion.19

To determine whether the inhibitory effect of GLP-1 (7–36 amide) on acid secretion is exerted at the gastric level or whether it involves mainly neural mechanisms we have investigated its effects on pentagastrin induced acid secretion in patients previously treated for duodenal ulcer disease by selective vagotomy.

Methods

SUBJECTS

Two women and six men, mean age 67 (SEM 3) years, who were operated on for an uncomplicated duodenal ulcer in the period 1964–71 were studied. All had had a selective vagotomy and pyloroplasty a.m. Heineke-Mikulicz. The vagotomy was considered complete in all patients as evidenced by more than 90% reduction in insulin induced peak acid output three months and five years after the operation. Since the operation none of the subjects has had a history of recurrent ulcer disease or signs of gastric outlet obstruction. Because of the age of the vagotomised subjects, two groups of control subjects were also investigated. One consisted of three women and five men, mean age 23 (SEM 1) years, the other comprised five men and one women, mean age 61 (SEM 2) years. All subjects were investigated for infection with Helicobacter pylori using a serological method.20 The study was approved by the local ethics committee of Copenhagen and Fredriksberg County. Written informed consent was obtained from all volunteers before the study.
PEPTIDE
Synthetic, human GLP-1 (7–36 amide) was purchased from Peninsula (Peninsula Laboratories, Merseyside, St Helens, UK). The peptide was dissolved in 0·9% saline containing 1% human serum albumin (Albumin Nordisk, Novo Nordisk, Gentofte Denmark, guaranteed to be free of hepatitis B surface antigen and human immuno-deficiency virus (HIV) antibody), subjected to sterile filtration, checked for sterility and pyrogens, and kept at −20°C until use. All experiments were carried out using the same peptide batch.

EXPERIMENTAL PROCEDURE
After an overnight fast a gastric sump tube (Andersen tube AN 10, New York, USA) was placed in the antrum under fluoroscopic control, and the stomach was emptied. Throughout the experiment a non-absorbable tracer, ⁵⁷Co-cobalamin (Amersham, UK) dissolved in 1000 ml 0·9% saline containing 1·25 mg cobalamin and 1% human serum albumin, was infused intragastrically at a rate of 1 ml/min (approximately 22 kBq/h) through a separate polyvinyl catheter attached to the gastric tube. Gastric juice was aspirated in 15 minute periods by intermittent suction producing a subatmospheric pressure of 150 mm Hg. An equilibration period of 30 minutes was followed by a basal period of 30 minutes. Pentagastrin (Peptavlon; Zeneca Ltd, Macclesfield, Cheshire, UK) was then infused intravenously at a dose of 150 ng/kg/h for three hours. After 60 minutes of pentagastrin stimulation GLP-1 (7–36 amide) was infused for 60 minutes at a rate of 1 pmol/kg/min. After termination of the GLP-1 (7–36 amide) infusion, the pentagastrin infusion was continued for another 60 minutes.

LABORATORY ANALYSIS
The acidity of the gastric samples was determined by titration with 0·1 mol/l NaOH to pH 7·4 at 37°C using a titrator TT2, ABU 80 autoburet, Radiometer, Copenhagen, Denmark). The radioactivity of ⁵⁷Co in each gastric sample was measured in a gamma spectrometer and used to calculate the recovery of the gastric juice volume. Subsequently, acid secretory rates were corrected for this recovery. Osmolarity as an index of duodenogastric reflux was determined by freezing point reduction.

BLOOD SAMPLES
Blood samples were drawn from an antecubital vein every 30 minutes until the infusion of GLP-1 (7–36 amide) was started; then blood samples were drawn every 15 minutes throughout the experiment. Blood was drawn into chilled tubes containing EDTA and aprotinin (Trasylol®, Bayer, Leverkusen, Germany; 1000 KIU/ml) and centrifuged at 4°C; plasma was stored at −20°C until analysed.

RADIOIMMUNOASSAYS
Human GLP-1 (7–36 amide) was measured using synthetic GLP-1 (7–36 amide) as a standard (Peninsula), [²⁵¹I]labelled GLP-1 (7–36 amide), and antiserum 89390. The antibody has an absolute requirement for the amidated C-terminus of the molecule for binding. Blood glucose was determined by the hexokinase method.

STATISTICAL ANALYSIS
All results are presented as means (SEM). The mean acid output in the basal period (0–30 minutes), the two last 15 minute periods during pentagastrin stimulation alone (60–90 minutes), during GLP-1 (7–36 amide) infusion (120–150 minutes), and after GLP-1 (7–36 amide) infusion (180–210 minutes) were used for statistical analysis. The significance between groups was evaluated by analysis of variance (ANOVA) followed by Newman-Keuls’s multiple range test; p<0·05 was considered significant.

Results
The recovery of the gastric marker averaged 99 (2)% in the young controls, 100 (4)% in the age matched controls, and 96 (3)% in the patients (not significantly different). Osmolarity (Table 1) increased slightly in all subjects as a consequence of the pentagastrin infusion, but there were no significant differences between the groups and no effect of the GLP-1 (7–36 amide) infusion, indicating that differences in duodenogastric reflux did not influence the results.

Table 1

<table>
<thead>
<tr>
<th>Group</th>
<th>Basal (mEq/15 min)</th>
<th>Post-infusion (mEq/15 min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Young controls</td>
<td>205 (30)</td>
<td>196 (9)</td>
</tr>
<tr>
<td>Old controls</td>
<td>257 (12)</td>
<td>256 (17)</td>
</tr>
<tr>
<td>Patients</td>
<td>246 (11)</td>
<td>243 (24)</td>
</tr>
<tr>
<td></td>
<td>233 (13)</td>
<td>242 (18)</td>
</tr>
</tbody>
</table>

Values are expressed as means (SEM). No significant differences were found within or between experiments.

Wettergren, Wojdemann, Meisner, Stadl, Holt

Figure 1 and 2 show the acid secretion. In the controls acid secretion increased from 1·1 to 4·8 (0·5 mEq/15 min in the basal state to 4·8 (0·5 mEq/15 min in the young group and from 1·2 to 6·2 (1·5 mEq/15 min in the old group during infusion of pentagastrin. The GLP-1 (7–36 amide) infusion significantly decreased acid secretion to 3·3 (0·5 mEq/15 min and 4·6 (1·1) mEq/15 min respectively. After termination of the GLP-1 (7–36 amide) infusion, acid secretion returned to preinfusion concentrations (5·0 (0·6) mEq/15 min and 5·9 (1·2) mEq/15 min). In the patients basal acid secretion averaged 0·1 (0·05) mEq/15 min. Pentagastrin increased acid secretion to 9·9 (0·4) mEq/15 min, but GLP-1 (7–36 amide) had no effect on this stimulated rate of secretion (1·8 (0·3) mEq/15 min during

Table 1: Osmolarity (mosmol/l) of gastric juice in controls and patients during submaximal pentagastrin stimulation before and after (period 1 and 2) concurrent GLP-1 (7–36 amide) infusion (period 2)
GLP-1 (7–36 amide) infusion and 1·8 (0·4) mEq during the last 60 minutes. Figure 3 shows that GLP-1 (7–36 amide) infusion increased plasma concentrations of GLP-1 (7–36 amide) from 5 (1) pmol/l to a plateau of 42 (6) pmol/l and 58 (6) pmol/l in the young and old control groups, respectively, and from 7 (1) pmol/l to 72 (6) pmol/l in the patients. There was no significant difference between the plateaux in the patients and the old controls. The GLP-1 (7–36 amide) infusion significantly and equally effectively decreased blood glucose concentrations in all groups (Table II).

Six out of eight vagotomised subjects were *H pylori* positive, whereas one out of the six old controls and one out of the eight young controls were positive. In both of the two positive control subjects GLP-1 (7–36 amide) clearly inhibited gastric acid secretion. There was no inhibition by GLP-1 (7–36 amide) in any of the vagotomised subjects regardless of *H pylori* status.

Discussion

The present study shows that the inhibitory effect on pentagastrin stimulated acid secretion in humans of GLP-1 (7–36 amide), infused in an amount that increases its plasma concentration to concentrations similar to those seen during meal ingestion, is lost after vagotomy. In the young controls the GLP-1 (7–36 amide) infusion caused a 33 (6)% reduction in acid secretion as expected,16 17 and in the old controls acid secretion decreased to 74 (3)% of plateau values, excluding that the lack of inhibition in the older vagotomised subjects was a consequence of age. Besides, the blood glucose lowering effect of GLP-1 (7–36 amide), which is thought to reflect a direct effect of GLP-1 (7–36 amide) on the pancreatic islet cells,13 was similar in all three groups. In a recent study, Olbe et al15 found that the inhibition of gastric acid elicited by antral distension was lost in patients infected with *H pylori*. Six out of our eight vagotomised patients were *H pylori* positive, but the remaining two, as in the others, failed to show inhibition of acid secretion with GLP-1 (7–36 amide). Furthermore, in both of the two positive controls GLP-1 (7–36 amide) was fully effective. A *H pylori* infection, therefore, is not likely as an explanation of the lack of effect of GLP-1 (7–36 amide) after vagotomy. Hypothetically, vagotomised subjects might be less sensitive to GLP-1 (7–36 amide) than normal subjects. However, we used an infusion rate that in normal subjects is maximally or near maximally effective.34 In addition, despite identical rates of infusion in all groups, the GLP-1 (7–36 amide) concentrations obtained in the vagotomised subjects tended to be higher than in the old controls and were significantly higher than in the young controls. Thus we find it unlikely that an inadequate

**Table I.** Blood glucose (mmol/l) in controls and vagotomised subjects during submaximal pentagastrin stimulation before and after (period 1 and 3) concurrent GLP-1 (7–36 amide) infusion (period 2).

<table>
<thead>
<tr>
<th></th>
<th>Young controls</th>
<th>Old controls</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Period 1</td>
<td>5·2 (0·4)</td>
<td>4·5 (0·2)</td>
<td>5·1 (0·4)</td>
</tr>
<tr>
<td>Period 2</td>
<td>4·4 (0·2)*</td>
<td>4·0 (0·1)*</td>
<td>4·1 (0·4)*</td>
</tr>
<tr>
<td>Period 3</td>
<td>5·4 (0·3)</td>
<td>4·3 (0·1)</td>
<td>4·8 (0·4)</td>
</tr>
</tbody>
</table>

Values are expressed as means (SEM).

*p<0·05 v periods 1 and 3.
concentrations of GLP-1
rate decreasing but ineffective stimulated secretion. This seems to indicate that GLP-1 (7–36 amide) receptors associated with vagal afferenents, central nervous sites, or transmission in vagal efferents. In experiments with isolated perfused preparations of the porcine stomach we have been unable to detect effects of intraarterially infused GLP-1 (7–36 amide) at a concentration of 10^{-9} mol/l on pentagastrin or vagally induced acid secretion (in six perfusion experiments, unpublished studies by the authors) whereas GLP-1 (7–36 amide) effectively inhibited vagally induced acid secretion in anaesthetized pigs. We were unable to find inhibitory or other effects of GLP-1 (7–36 amide) on vagally induced pancreatic exocrine secretion in vagally innervated, isolated perfused preparations of the porcine pancreas. This would indicate that GLP-1 (7–36 amide) probably does not interfere with vagal efferent transmission at the level of the parasympathetic ganglia. At present, experimental evidence that GLP-1 (7–36 amide), interacts withafferent vagal fibres (as cholecystokinin does) is not available. An interaction with central nervous sites seems probable, however. Several groups have noted binding sites or receptors for GLP-1 (7–36 amide) in the brain. Indeed, a receptor identical to the pancreatic GLP-1 (7–36 amide) receptor was recently cloned from human brain. Of particular interest is the demonstration of GLP-1 (7–36 amide) binding sites in nuclei associated with the circumventricular organ. This might indicate that GLP-1 (7–36 amide), released from the small intestine, could reach the brain via these leaks in the blood–brain barrier as recently shown for rats, in which intracar diaally injected labelled GLP-1 (7–36 amide) specifically bound to cells of the subfornical organ and the area postrema, clearly crossing the blood–brain barrier. Interestingly, both of these are associated with digestive behaviour. Clearly, further studies are needed to identify in more detail the exact site of action of this hormone, which has been proposed to act as an important effector of the “ileal brake” mechanism – that is, the inhibitory endocrine signal from the lower to the upper gastrointestinal tract.

This study was supported by the Danish National Research Council. Inge Mortensen, Winni Stavstrup and Lene Albek are thanked for excellent technical assistance.


GLP-1 influences vagal activity

34 Ørskov C, Poulsen SS, Møller M, Holst JJ. GLP-1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide-1. *Diabetes* 1996; 45: 832–5.
The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation.

A Wettergren, M Wøjdemann, S Meisner, F Stadil and J J Holst

Gut 1997 40: 597-601
doi: 10.1136/gut.40.5.597